[1]
|
X. Q. Liu and L. L. Qu, “The Clinical Characteristic, Current Therapeutic Situation and Tendency of Non- Small-Cell Lung Carcinoma in Advanced Stage,” Chinese Oncology Clinical Album, 2007, pp. 184-189.
|
[2]
|
M. Duruisseaux, J. Cadranel, E. Biron, M. Pérol, J. C. Guérin and D. Arpin, “Major and Prolonged Response to Pemetrexed in Two Cases of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features,” Lung Cancer, Vol. 65. No. 3, 2009, pp. 385-387.
doi:10.1016/j.lungcan.2009.02.018
|
[3]
|
M. Duruisseaux, J. Cadranel, M. Pérol and D. Arpin, “The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features,” Current Drug Targets, Vol. 11, 2010, pp. 74-77. doi:10.2174/138945010790031045
|
[4]
|
T. Sasaki, H. Yasuda, K. Nakayama, M. Asada, S. Okinaga, T. Suzuki, et al., “Pleurodesis with Carboplatin in Elderly Patients with Malignant Pleural Effusion and Lung Adenocarcinoma,” Journal of the American Geriatrics Society, Vol. 54, No. 4, 2006, pp. 722-723.
doi:10.1111/j.1532-5415.2006.00668_9.x
|
[5]
|
W. D. Travis, E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger, Y. Yatabe, et al., “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” Journal of Thoracic Oncology, Vol. 6, No. 2, 2011, pp. 244-285. doi:10.1097/JTO.0b013e318206a221
|
[6]
|
L. Crinò, F. Cappuzzo, P. Zatloukal, M. Reck, M. Pesek, J. C. Thompson, et al., “Gefitinib versus Vinorelbine in Chemotherapy-Naive Elderly Patients with Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study,” Journal of Clinical Oncology, Vol. 26, No. 26, 2008, pp. 4253-4260.
|
[7]
|
G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, et al., “EGFR and K-ras Mutations along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors,” Journal of Clinical Pathology, Vol. 131, 2009, pp. 478-489. doi:10.1309/AJCPH0TRMPXVZW2F
|
[8]
|
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark and F. A. Shepherd, “Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21,” Journal of Clinical Oncology, Vol. 26, No. 4, 2008, pp. 2350-2357. doi:10.1200/JCO.2007.15.2280
|
[9]
|
J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton, et al., “Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab with Maintenance Pemetrexed and Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3284-3289. doi:10.1200/JCO.2008.20.8181
|
[10]
|
H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, et al., “Nitroglycerin Treatment may Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma,” Clinical Cancer Research, Vol. 12, 2006, pp. 6748-6757.
doi:10.1158/1078-0432.CCR-06-1124
|
[11]
|
L. Balducci, C. L. Hardy and G. H. Lyman, “Hemopoietic Reserve in the Older Cancer Patient: Clinical and Economic Considerations,” Cancer Control, Vol. 7, No. 6, 2000, pp. 539-547.
|
[12]
|
Elderly Lung Cancer Vinorelbine Italian Study Group. “Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients with Advanced Non-Small-Cell Lung Cancer,” Journal of National Cancer Institution, Vol. 91, No. 1, 1999, pp. 66-72. doi:10.1093/jnci/91.1.66
|
[13]
|
C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, et al., “Chemotherapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial,” Journal of National Cancer Institution, Vol. 95, No. 5, 2003, pp. 362-372. doi:10.1093/jnci/95.5.362
|
[14]
|
K. Takeda, T. Hida, T. Sato, M. Ando, T. Seto, M. Satouchi, et al., “Randomized phase III Trial of Platinum- Doublet Chemotherapy Followed by Gefitinib Compared with Continued Platinum-Doublet Chemotherapy in Japanese Patients with Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203),” Journal of Clinical Oncology, Vol. 28, No. 5, 2010, pp. 753-760.
doi:10.1200/JCO.2009.23.3445
|
[15]
|
N. Hanna, F. A. Shepherd, F. V. Fossella, J. R. Pereira, F. De Marinis, J. von Pawel, et al., “Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non–Small-Cell Lung Cancer Previously Treated with Chemotherapy,” Journal of Clinical Oncology, Vol. 22, No. 9, 2004, pp. 1589-1597.
doi:10.1200/JCO.2004.08.163
|
[16]
|
S. Kudoh, K. Takeda, K. Nakagawa, M. Takada, N. Katakami, K. Matsui, et al., “Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904),” Journal of Clinical Oncology, Vol. 24, No. 22, 2006, pp. 3657-3663. doi:10.1200/JCO.2006.06.1044
|
[17]
|
C. Delbaldo, S. Michiels, N. Syz, J. C. Soria, T. Le Chevalier and J. P. Pignon, “Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer a Meta-Analysis,” The Journal of American Medical Association, Vol. 292, 2004, pp. 470-484. doi:10.1001/jama.292.4.470
|
[18]
|
C. J. Langer, J. Manola, P. Bernardo, J. W. Kugler, P. Bonomi, D. Cella, et al., “Cisplatin-Based Therapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial,” Journal of National Cancer Institution, Vol. 94, 2002, pp. 173-181.
|
[19]
|
G. V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, et al., “Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 26, No. 21, 2008, pp. 3543-3551.
doi:10.1200/JCO.2007.15.0375
|
[20]
|
T. Ciuleanu, T. Brodowicz, C. Zielinski, J. H. Kim, M. Krzakowski, E. Laack, et al., “Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study,” Lancet, Vol. 371, 2009, pp. 1432-1440.
doi:10.1016/S0140-6736(09)61497-5
|
[21]
|
F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, et al., “Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non- Small-Cell Lung Cancer: A Review of the Literature,” Oncologist, Vol. 12, No. 4, 2007, pp. 451-464.
doi:10.1634/theoncologist.12-4-451
|